Chimeric antigen receptor T-cell immunotherapy (First Affiliated Hospital of Zhejiang University)

N/A

Report date: 2024/12/19 14:04:22

Base Information

Drug NameChimeric antigen receptor T-cell immunotherapy (First Affiliated Hospital of Zhejiang University)

Drug Alias NameAnti-CD19 CAR T cells expressing inducible IL-7 and CCL19嵌合抗原受体T细胞免疫疗法-浙江大学

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaPending

Originator CompaniesZhejiang University First Affiliated Hospital Of Zhejiang University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesFirst Affiliated Hospital Of Zhejiang University

Active IndicationsN/A

Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A